About us

Boost Beyond Boundaries

History

Astrogen History

With years of clinical experience, Astrogen is exploring new horizons
in medications development field at an unprecedented speed.

  • June Selected for "Unicorn Bridge" by Ministry of SMEs and Startups
  • Participation in BIO International Convention 2026
  • February Received the "Folia Award" for AST-001 Phase 2 Clinical Trial Paper (PCN Journal)
  • January Signed License-Out Agreement for AST-001
  • across 16 Middle Eastern Countries (USD 200M + Royalties)
2026
2026
2025
2025
  • September Selected as a Preliminary Unicorn Company
  • Selected for the SME Technology Innovation Development Project
  • June Submitted NDA for AST-001 (Speregen) to MFDS
  • December Last subject observation completed for AST-001 Phase 3 Clinical Trial
  • Publication of AST-001 PK/PD modeling study in Frontiers in Pharmacology (SCI journal)
  • November Designation as an Excellent Corporate Research Institute for the second half of 2024
  • October Publication of AST-001 Phase 2 clinical results in Psychiatry and Clinical Neurosciences (SCI journal)
  • June Participation in BIO USA 2024
  • Acquiring an Orphan Drug Designation (ODD) from MFDS
  • April Selected as ‘Super Gap Startup 1000+ Project’ by the Ministry of SMEs and Startups
  • January Received the investment of Series C (KRW 12.5 billion)
2024
2024
2023
2023
  • October Oral presentation of AST-001 Phase 2 results abstract (AACAP 70th Annual Meeting)
  • Certified as INNO-BIZ
  • September Clinical Study Report for AST-001 Continuous Treatment Follow-up Study (CSR)
  • August First subject enrolled in AST-001 Phase 3 Clinical Trial
  • ISO 9001 certification
  • ISO 14001 certification
  • ISO 45001 certification
  • July Selected for the "Baby Unicorn Plus Company" by the Ministry of SMEs and Startups
  • May Last subject observation completed for AST-001 Continuous Treatment Follow-up Study
  • August Selected as Employment-Friendly Company by Daegu City
  • Selected as BIG3 projects by the Ministry of SMEs and Startups
  • Designated as Startup Growth Technology Development Project
  • Received the investment of Bridge 2 (KRW 3 billion)
  • June Publication of AST-001 PK modeling study in Frontiers in Pharmacology (SCI journal)
  • May Completed observation for the final subject of the phase 2 clinical trial for AST-001
  • February Received the investment of Bridge 1 (KRW 9 billion)
  • January First subject enrolled in the AST-001 Continuous Treatment Follow-up Study
2022
2022
2021
2021
  • December Received Presidential Citation for Venture Startup Promotion Merit Award
  • Certified as a "Family-Friendly Company" by the Ministry of Gender Equality and Family
  • November Designated as Excellent Corporate R&D Center by the Ministry of Science and ICT
  • October Introduced Astrogen’s ESG ethical management
  • September Uploaded the Astrogen ESG Report on the website
  • Selected as a "Pre-Star Company" by the Daegu Metropolitan Government
  • February Phase 1 Clinical Study Report for AST-001 (CSR)
  • Enrolled the first trial subject in the phase 2 clinical trial for AST-001
  • December Received the investment of Series B (KRW 13 billion)
  • Received Grand Prize at the Daegu Startup Awards by the Daegu Center for Creative Economy Innovation
  • Received Minister Award from the Ministry of Trade, Industry and Energy for revitalizing free economic zone
  • November Selected as the "National Representative Innovative Company'" by the Financial Services Commission
  • August Opened the Astrogen's Pharmaceutical Research Institute (Naju) Office
  • July Received approval of IND application for phase 2 clinical trial for AST-001
  • June Selected as a "Baby Unicorn Plus Company" by the Ministry of SMEs and Startups
  • May Completed construction of Astrogen’s new office building
  • March Received IND for phase 1 clinical trial for AST-001
2020
2020
2019
2019
  • December Started construction of Astrogen’s new building and research center
  • November Selected as the Frontier Venture Company by the Korea Technology Finance Corp. (KIBO)
  • Selected as an "A+ Member" by KIBO
  • August Received the investment of Series A (KRW 5 billion of capital increase)
  • May Obtained the approval to move into the Daegu-Gyeongbuk Medical Cluster
  • March Opened the Astrogen's Business Development Division (Seoul) office
  • August Pre-Series A SEED (KRW 1.9 billion of capital increase)
  • January Obtained the approval for Astrogen Research Center
2018
2018
2017
2017
  • July Founded Astrogen, inc.
  • Obtained Venture Company certification